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Background: Primary chest wall tumors originate from different constructions of thoracic wall. We report our
multidisciplinary experience on primary thoracic tumor resection and thoracic reconstruction, the need to
additional therapy and evaluating prognostic factors affecting survival.
Methods: We performed a retrospective review of our prospectively maintained database of 40 patients treated
for malignant primary chest wall tumor from 1989 to 2009. Patients were evaluated in terms of age, sex, clinical
presentation, type of imaging, tissue diagnosis methods, pathology, surgical technique, early complications, hospital
mortality, prevalence of recurrence and distant metastases, additional treatment, 3 years survival and factors
affecting survival.
Results: Male/Female (F/M) = 1, with median age of 43.72 years. Mass was the most common symptoms and the
soft tissue sarcoma was the most common pathology. Resection without reconstruction was performed in 5
patients and Thirty-five patients (87.5%) had extensive resection and reconstruction with rotatory muscular flap,
prosthetic mesh and/or cement. Overall, 12.5% (5/40) of patients received neoadjuvant therapy and 75% (30/40) of
patients were treated with adjuvant therapy. The 3-year survival rate was 65%. Recurrences occurred in 24 patients
(60%), 14 developed local recurrences, and 10 developed distant metastases. The primary treatment modality for
both local and distant recurrences was surgical resection; among them, 10 underwent repeated resection, 9
adjuvant therapy and 5 were treated with lung metastasectomy. The most common site of distant metastasis
was lung (n = 7). Factors that affected survival were type of pathology and evidence of distant metastasis.
Conclusion: Surgery with wide margin is the safe and good technique for treatment of primary chest wall tumors
with acceptable morbidity and mortality.
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Primary chest wall tumors involve a wide various
groups of soft tissue and skeletal structures of thorax.
They originate from different constructions of the
thoracic wall and may occur in 2 main tissue types:
single and combined. Owing to the few number of
such lesions, diagnosis and appropriate therapeutic
approach is needed and further evaluations should be
considered. There are various ways to diagnose these* Correspondence: Emis@mums.ac.ir
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reproduction in any medium, provided the ortumors including: fine needle aspiration and biopsy
(FNA & B), incisional and excisional biopsy. Chest
wall tumors have been classified according to these
criteria: cell type, involved tissue, sensitivity to radi-
ation and benign against malignant [1].
Malignant primary tumors are mostly symptomless
and grow slowly. With the extension of these masses,
pains occur. Chest wall resection due to diverse etiolo-
gies can cause extensive chest wall defects which may
involve soft and skeletal tissues. There are 2 ways to
cover deep chest wall defects: prosthetic or biologic
mesh and/or soft tissue flaps with excellent blood supply
[2,3]. Surgeons are not always able to close the defectl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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and are given adequate margins [4].
Titanium implants in combination with synthetic or
biologic mesh can be a safe and effective way of recon-
structing large full thickness chest wall defects. Recon-
struction varies according to the origin of the tumor:
mesh and cement is used to reconstruct tumors originat-
ing from bone tissue, while and in soft tissue sarcomas
muscular flap is administered [3].
The aim of this study is to evaluate the outcomes of
surgical treatment in malignant primary chest wall tu-
mors, and the factors affecting survival.Figure 2 Resected specimen of patient with chest wall tumor.Methods
Between 1989 and 2009, this case-series study was per-
formed on 40 patients with primary chest wall tumors,
who underwent chest wall reconstruction at Qaem and
Omid Hospital of Mashhad University of Medical Sciences-
Iran. Follow-up period was 3 years.
Inclusive criteria: 1) malignant primary chest wall
tumor with definitive pathologic diagnosis 2) perform-
ing appropriate surgery 3) three years follow up after
surgery.
Exclusive criteria: 1) Other types of chest wall tumors
(benign or metastatic) 2) inadequate surgical treatment
3) less than three years follow up.
Patients were evaluated in terms of: age, sex, clinical
presentation, type of imaging, tissue diagnosis methods,
pathology, surgical technique, early complications, hos-
pital mortality, prevalence of recurrence and distant me-
tastases, additional treatment, 3 years survival and factors
affecting survival. This article is approved in regional ethic
committee of Mashhad University of Medical Sciences
(project number: 89844).Figure 1 CT scan of a patient with chest wall tumor.Statistical analysis
All data were analyzed using SPSS software. Kruskal-
Wallis test, Mann-Whitney test and Chi-Square were ap-
plied. P-Value < 0.05 was statistically significant.
Result
There were 20 men and 20 women, aged 11 to 86 years,
with a median age of 43.72 years. Clinical presentations
were: palpable mass (97.5%, of them, 20% were tender),Figure 3 Technique of reconstruction. Black arrow: Meshed and
cement, White arrow: Latissimus dorsi muscle flap.
Figure 4 Type of surgery in our patient.
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puted tomography was performed for all patients; how-
ever, MRI was done in only 15 patients (37.5%) to assess
neurovascular involvement. Figure 1 showed CT scan of
patients with chest wall tumors.
There were 3 diagnostic procedures; fine needle aspir-
ation and biopsy (FNA & B) was performed in all pa-
tients, of them, it was diagnostic in 5 patients (12.5%).
Hence, tissue samples were obtained by 2 other methods
in 35 patients. Incisional biopsy in 8 patients with tumor
more than 4cm in size (20%) and excisional biopsy in 27
cases with tumor less than 4cm (67.5%). According to
pathology results, patients were classified into 6 groups:
soft-tissue sarcoma (18 patients, 45%), chondrosarcoma
(12 patients, 30%), osteosarcoma (6 patients, 15%), small
round cell tumor (4 patients, 10%), plasmacytoma (4 pa-
tients, 10%), giant cell tumor (1 patient, 2.5%). In our
series, 18 out of 40 primary chest wall tumors were soft
tissue sarcoma. Soft tissue sarcoma was the most com-
mon primary chest wall tumor, and MFH was the mostFigure 5 Distant metastases and local recurrence Figure.common pathology among soft sarcomas (33%, and 15%
of total tumors).
35 out of 40 tumors (87.5%) arise from both soft tissue
and adjacent ribs and other 5 tumors (12.5%) originated
from sternum. Adequate margin of resection was 4cm.
Moreover, reconstruction was required in anterior tu-
mors sized more than 5cm and posterior tumors more
than 10cm. five patients underwent resection without re-
construction: 2 with Low grade malignant fibrous histio-
cytoma (MFH), 1 with costal Chondrosarcoma, 1 with
Liomyosarcoma and 1 Fibrosarcoma.
Resection was performed in 4 men and 1 woman.
Moreover, extensive resection and reconstruction was
done in 19 women and 16 men. Figure 1 and Figure 2
showed resected specimen and the use of mesh and ce-
ment in combination with muscle flap in reconstruction.
Latissimus dorsi flap was the common muscle flap
used in our work (30 patients). In five patients with ster-
nal resection bilateral pectoral muscle flap was used
(Figure 3). Figure 4 shows technique in surgical resection.
Figure 6 Need for adjuvant therapy.
Table 1 This table shows the prognostic factors affecting
in survival
Factors affecting survival Survey [N(%)] P.
valueGood Bad
Age (mean ± SD) 44.80 ± 18.3 41.71 ± 19.7 0.62
Sex
Male 12 (30) 14 (35)
0.50
Female 8 (20) 6 (15)
Histopathology
Soft sarcoma 15 (37.5) 3 (7.5) 0.03
Osteosarcoma + chondrosarcoma 3 (7.5) 1 (2.5) 0.11
Soft sarcoma + chondrosarcoma 0 1 (2.5) 0.35
Chondrosarcoma 7 (17.5) 5 (12.5) 0.72
Osteosarcoma 2 (5) 4 (10) 0.16
Round cell 0 4 (10) 0.01
Plasmacytoma 2 (5) 2 (5) 0.60
Giant cell tumor 1 (2.5) 0 0.65
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4 patients with wound infection (10%), 2 with sarcoma
(5%) and in 2 other patients atelectasia occured (5%). All
of these 8 patients were treated with medical therapy.
Hospital mortality was 0% (defined as death during 30
days after operation). Prevalence of local recurrence and
distant metastasectomy are detailed in Figure 5.
Extra pulmonary metastases originated differently: bone
(2.5%), liver (2.5%), retroperitoneal (2.5%). These 3 pa-
tients with extra pulmonary metastasis underwent adju-
vant therapy.
2 different approaches administered in 7 patients with
pulmonary metastasis: metastasectomy and adjuvant ther-
apy were performed in 5 and 2 patients respectively
(12.5% and 5%). The need for adjuvant therapy showed
in Figure 6.
3 years survival was 65%. 14 patients died during fol-
low up, of these, 8 were men and 6 were women. The
most mortal pathologies were: round cell tumor (4 cases),
soft tissue sarcoma and osteochondroma (3 patients each),
plasmacytoma (2 cases), osteosarcoma and chondrosar-
coma (1 patient each). Table 1 shows factors that affected
survival of our patients.
Our purpose is to discuss the role of operative tech-
nique and tissue pathology in survival. In this study, we
report our multidisciplinary experience with primary chest
wall sarcomas that included induction (adjuvant and neo-
adjuvant) therapy. 3 years disease-free survival was esti-
mated 65 %( 26 patients). Patients with round cell tumor
and soft sarcoma have high mortality rate and also distant
metastasis is one of the main factors affecting survival
(P_value: 0.011, 0.028 and 0.00 respectively).Technique of surgery
Resection 5 (12.5) 0
0.14
Resection and reconstruction 21 (52.5) 14 (35)
Distant metastasis
Yes 0 26 (65)
0.001
No 10 (25) 4 (10)Discussion
Primary chest wall tumors are not common and are pre-
sented with different symptoms. Patients usually get
symptomatic with palpable mass, pain or both at the site
of the tumor [1,5].They may arise from diverse structure of the thoracic
wall [6].
Reconstruction of the chest wall is a reliable efficient
management in patients with chest wall tumors. Other
treatment alternating reconstruction surgeries are as fol-
lows: 1-various types of flaps (skin, muscle, myocuta-
neous, transferred ones from another location and free
flaps); 2- to close the defect primarily [7].
In 2011, a study by Guo L et al. revealed that single
or combined flaps are useful to repair soft tissue defect.
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vere and extensive defect to reconstruct thoracic skel-
eton [8].
In a study performed on 11 cases with primary thoracic
sarcoma, D’Alessandro P at al. cited that a safe and effective
one stage surgical procedure for various chest wall defects
is tumor resection and reconstruction using prosthetic
mesh [9].
Also, in 2012, Berthet JP et al. discussed that titanium
implants in combination with strong synthetic or bio-
logic mesh in a one-stage procedure can safely use for
reconstructing major chest wall defects [3].
A retrospective study performed on 5 patients de-
scribed the use of biologic mesh as a safe and depend-
able alternative to synthetic prostheses and tissue repair
in pediatric chest wall reconstruction [10].
Between 2005 and 2009, Bosc R and colleagues per-
formed post-resection reconstruction in 22 patients with
primary or metastatic chest wall tumors. They con-
cluded that full-thickness chest wall resection has pro-
longed palliation and cure in these patients [2].
In 2012, 51 patients with primary chest wall sarcomas
underwent full-thickness resection. The majority of high
risk sarcomas (including: soft tissue, bony and desmoids
tumors) were treated. Kachroo P et al. cited that local
and distal recurrence may be decreased by neoadjuvant
systemic therapy and improve survival [11].
There are different factors affecting the type of the re-
construction. In 2010, Tepliakov VV et al. pointed out
that the extension of the resected site; cosmetic out-
comes of the tissue flaps and localization of the tumor
are some of the affecting factors. They also cited that the
cornerstone in treating thoracic wall tumors is surgical
methods [12].
Pathology of primary chest wall tumors obtained by
thin sections is too varied and results in different out-
comes and survival. A study by James B et al. on 23 pa-
tients with malignant tumors revealed that only 13% of
tumors of skeletal origin have more than five years sur-
vival [1].
In 2011, Girotti P and colleagues performed a study
on 101 patients with sternal tumors. They described that
local complication rate may be reduced by an adequate
sternal resection at the first operation and prosthetic in-
tegration with surrounding tissues [13].
A study by Otsuka T and coauthors revealed that in
patient with malignant fibrous histiocytoma (MFH) re-
section and reconstruction surgery has good results [14].
In 2013, a study by McMillan RR et al. on 192 patients
who underwent resection for soft tissue sarcoma of the
chest wall revealed that, local or distant recurrences of
soft tissue sarcomas commonly occurred after surgical
resection, but, both can make reasonable results if
treated with resection [15].Conclusion
Surgery with wide margin is the safe and good technique
for treatment of primary chest wall tumors with accept-
able morbidity and mortality.
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